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Key Points
Question
To what extent are adolescents with preexisting mental health conditions more likely than adolescents
without those conditions to receive long-term opioid therapy?
Findings
In a cohort of more than 1 million commercially insured adolescents receiving opioids nationwide, 3.0 per
1000 recipients transitioned to long-term opioid therapy within 3 years. Adolescents with a range of prior
mental health conditions and treatments had substantially higher rates of transitioning from initial opioid
receipt to long-term opioid therapy.
Meaning
Long-term opioid therapy rates were low among commercially insured adolescent opioid recipients overall
but were substantially higher among those with preexisting mental health conditions and treatments.
Abstract
Importance
Adults with mental health conditions are more likely than those without to receive long-term opioid
therapy. Less is known about opioid therapy among adolescents, especially those with mental health
conditions.
Objective
To examine associations between preexisting mental health conditions and treatments and initiation of any
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opioid and long-term opioid therapy among adolescents.
Design, Setting, and Participants
A cohort of 1 224 520 incident opioid recipients without cancer diagnoses aged 14 to 18 years at first
receipt was extracted from nationwide commercial health care claims data from January 1, 2003, to
December 31, 2014. Analysis was conducted from August 19, 2016, to November 16, 2017. Associations
between preexisting mental health conditions and treatments and any opioid receipt were examined by
comparing recipients with nonrecipients matched on sex, calendar year and years of age of first enrollment,
and months of enrollment (prior to the index month for recipients, ever for nonrecipients). Associations
between preexisting mental health conditions and treatments and subsequent long-term opioid therapy were
examined among recipients with at least 6 months’ follow-up using Cox proportional hazards regressions
adjusted for demographics.
Exposures
Mental health condition diagnoses and treatments recorded in inpatient, outpatient, and filled-prescription
claims prior to opioid receipt.
Main Outcomes and Measures
Opioid receipt, defined as any opioid analgesic prescription claim, and long-term opioid therapy, defined as
more than 90 days’ supply within a 6-month window having no gaps in supply of more than 32 days.
Results
Of the 1 224 520 new opioid recipients included, the median age at first receipt was 17 years (interquartile
range, 16-18 years), and 51.1% were female. Median follow-up after first receipt was 625 days
(interquartile range, 255-1268 days). Adolescents with anxiety, mood, neurodevelopmental, sleep, and
nonopioid substance use disorders and most mental health treatments were significantly more likely to
receive any opioid (odds ratios from 1.13 [95% CI, 1.10-1.16] for nonopioid substance use disorders to
1.69 [95% CI, 1.58-1.81] for nonbenzodiazepine hypnotics). Among the 1 000 453 opioid recipients
(81.7%) who had at least 6 months’ follow-up, the cumulative incidence of long-term opioid therapy was
3.0 (95% CI, 2.8-3.1) per 1000 recipients within 3 years after first opioid receipt. All preexisting mental
health conditions and treatments were strongly associated with higher rates of long-term opioid therapy
(adjusted hazard ratios from 1.73 [95% CI 1.54-1.95] for attention-deficit/hyperactivity disorder to 8.90
[95% CI, 5.85-13.54] for opioid use disorder).
Conclusions and Relevance
Commercially insured adolescents with many types of preexisting mental health conditions and treatments
were modestly more likely to receive any opioid and were substantially more likely to subsequently
transition to long-term opioid therapy relative to those without, although overall rates of long-term opioid
therapy were low.
Introduction
Opioid analgesics are the controlled medications most commonly prescribed to adolescents.  An estimated
2.9% of US children and adolescents received prescription opioids in 2012.  Adolescents treated with
opioids are at risk of negative consequences. For example, hospitalizations associated with prescription
opioid poisoning were 10.2 per 100 000 adolescents in 2012.
Against the background of 33 091 total opioid overdose deaths in 2015  and increasing attention to opioid
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therapy for adults with chronic pain,  identifying appropriate prescription practices and concomitant
treatment needs for adolescents receiving opioids is essential. Yet little is known about long-term opioid
therapy (LTOT) patterns or safety among adolescents.  Among adults, there is clear evidence that those
patients at greatest risk of adverse opioid-related outcomes—notably including those with preexisting
substance use disorder (SUD) and other mental health conditions —are actually most likely to receive
prescribed opioids in greater quantities.  Limited evidence supports similar prescription patterns among
adolescents.
Given the rarity of LTOT among youths, however, few studies have had sufficient sample sizes to examine
associations between LTOT and specific mental health conditions during adolescence in particular.  Our
previous report used nationwide commercial health care insurance claims to demonstrate increased rates of
LTOT among patients, including adolescents and young adults, with mental health conditions and
treatments.  The present study used the same data source to focus exclusively on adolescents aged 14 to
18 years initiating opioid receipt. Specifically, we examined initial opioid receipt and the subsequent
transition to LTOT with the goal of evaluating associations across a wide range of preexisting mental health
conditions and their treatments. The large scale of the study permitted consideration of rare yet serious
conditions (eg, youth-onset opioid use disorder [OUD] and self-injurious behavior) and potentially harmful
combined therapies (eg, benzodiazepines ).
Methods
Data Source
This study used data from the 2003-2014 Truven Health MarketScan Commercial Claims and Encounters
(MarketScan) databases of commercial health care insurance claims. Approximately half of the US
population had commercial insurance in 2014, and MarketScan data include claims for inpatient and
outpatient services and filled prescriptions obtained from employers and health plans.  There were
approximately 154 million unique enrollee observations from 2003 to 2014, including employees, their
spouses and dependents, COBRA (Consolidated Omnibus Budget Reconciliation Act) continuers, and early
retirees. This study was determined to be exempt by the Indiana University and University of Chicago
institutional review boards, and the need for patient informed consent was waived because no personal
identifiers were involved.
Opioid Recipient Sample
We identified a cohort of adolescents who filled an initial opioid prescription. Of the 2 308 252 MarketScan
enrollees aged 14 to 18 years initiating opioid receipt, 1 283 773 (55.6%) were enrolled for at least 12
consecutive calendar months prior to the month of the index (first) opioid prescription fill and were
therefore considered new recipients. Months with any covered days were counted as enrolled, including
only those years in which enrollees had prescription coverage. We subsequently excluded patients who had
received a cancer diagnosis in the year before or 1.5 years after the index prescription (n = 55 692) or those
without valid enrollment at the time the index prescription was filled (n = 3561), resulting in a sample of 1 
224 520 patients (53.0% of all adolescent initiators). We followed up enrollees from their index prescription
until their first disenrollment or December 31, 2014 (whichever occurred first), to examine subsequent
LTOT. To compare opioid recipients with nonrecipients, we also identified a sample of control patients who
filled no opioid prescriptions, matched 1:1 to recipient cases.
Opioid Prescription
We identified prescription claims for any opioid analgesic.  Nontransdermal buprenorphine hydrochloride
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Any Opioid Receipt
was excluded because it was assumed to have been used for OUD treatment.  By contrast, prescription
claims for methadone hydrochloride were included because they are unlikely to represent methadone
treatment of OUD, which is likely to be recorded in other service claims.  All opioid prescriptions (and all
patients with index prescriptions) with dates outside the included years, days’ supply that were nonpositive
or more than 180 days, or quantities (eg, pills and milliliters of solution) that were nonpositive or more than
1000 were excluded to guard against invalid records.
We defined LTOT as receipt of more than 90 days’ supply of opioids within a 6-month window having no
gaps in supply greater than 32 days.  We considered the first fill date for a window meeting these
criteria the onset of LTOT. We determined, using fill dates and days’ supply, whether each day during
follow-up was covered by a prescription for any opioid, with 2 exceptions. First, we assumed that any
overlapping prescriptions for the same drug (eg, short-acting hydrocodone products) were taken
sequentially. Second, we assumed that buprenorphine transdermal patches were worn for 7 days, fentanyl
transdermal patches for 3 days, and that they were used sequentially.  We rounded the number of patches
up to the nearest integer when necessary to calculate integer days’ supply.
Prior Mental Health
We identified mental health conditions from inpatient or outpatient claims before the month of the first
opioid prescription receipt. Diagnoses were recorded in service claims using International Classification of
Diseases, Ninth Revision (ICD-9) codes for attention-deficit/hyperactivity disorder (ADHD), anxiety
disorders, bipolar or other (nondepressive) mood disorders, depressive disorders, nonopioid SUDs, OUD,
schizophrenia spectrum disorders, sleep disorders, and suicide attempt or other self-injury.
We identified prior psychoactive medications using claims for filled prescriptions of the following drug
classes: ADHD medications, antipsychotics, benzodiazepines, mood stabilizers, nonbenzodiazepine
hypnotics, OUD medications (ie, naltrexone products; buprenorphine with or without naloxone
hydrochloride, excluding the buprenorphine transdermal patch Butrans and the injectable buprenorphine
hydrochloride Buprenex), serotonin-norepinephrine reuptake inhibitors (SNRIs), and selective serotonin
reuptake inhibitors (SSRIs). To distinguish medications used in pain from medications used for psychiatric
treatment, we excluded duloxetine hydrochloride from the SNRIs and all antiepileptic drugs except
lamotrigine from the mood stabilizers. We also identified claims for psychotherapy, regardless of diagnosis
(Current Procedural Terminology, 4th Edition, codes 90804, 90816, 90806, 90818, 90808, 90821, 90845,
90846, 90847, 90849, 90853, 90832, 90834, and 90837). We required adolescents to be at least 13 years
old at claims for prior mental health diagnoses and treatments to avoid including claims of questionable
validity (eg, early childhood SUD). Diagnosis codes and generic medication names are provided in eTables
1 and 2 in the Supplement.
Statistical Analysis
We first used a matched case-control approach to examine whether prior mental
health conditions were associated with initial receipt of any opioid. Given the variability in enrollment and
demographics, we matched opioid recipients 1:1 to nonrecipient controls on exact values of sex, calendar
year and years of age of first enrollment, and months of enrollment (prior to the index month for recipients,
ever for nonrecipients).  For this enrollment length to correspond with eligibility for mental health
conditions and treatments, we only counted enrollment when enrollees were at least 13 years old.
Of the opioid recipients, 5.8% could not be matched to nonrecipients. Randomly selecting 40% of the
recipients yielded greater success (0.02% unmatched); thus, we used this subset for the matched-pair
analysis (n = 489 704 pairs). Selected recipients were similar to the full cohort on index age and year, sex,
months of prior enrollment, and opioid drugs received. We compared the odds of any opioid receipt
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Long-term Opioid Therapy
between matched recipients and nonrecipients by using separate conditional logistic regressions for each
predictor.
In our primary analyses, we used a cohort design to examine whether prior
mental health predicted the transition from initial opioid receipt to long-term therapy (ie, among opioid
recipients only). Because follow-up could be right censored, we used Kaplan-Meier estimates and separate
Cox proportional hazards regressions for each predictor, with time since index opioid prescription fill as the
time scale.  We also examined the number of different types of mental health conditions (0, 1, or 2+) to
index comorbidity.  Because our LTOT definition required 6-month windows, we set censoring dates to 6
months prior to the end of observed follow-up (ie, the last date at which an adolescent could begin a
6-month window). Thus, adolescents could begin LTOT at any time from index opioid fill until censoring.
This rule additionally required 6 months or more of follow-up, excluding 224 067 adolescents from these
analyses (n = 1 000 453). The Cox regressions were adjusted for sex, index age, and index year.
We conducted 5 sensitivity analyses. First, we restricted the sample to patients with painful condition
diagnoses in the 90-day period that ended with the index date to examine associations among adolescents
more likely to be receiving opioid therapy for those conditions (eTable 1 in the Supplement).  Second,
we included a linear time-by-predictor interaction to evaluate and account for potential violations of the
proportional hazards assumption. Third, we used a stricter definition of LTOT that required opioid supply
on every day within a 6-month window to examine the sensitivity of the associations to the outcome
criterion. Fourth, we counted only past year mental health claims so that all recipients had equivalent time
for predictors. Fifth, we restricted the sample to patients with 2010 index dates, which decreased the
likelihood of bias from (1) changes in data collection (MarketScan records include additional diagnosis
fields from 2009 onward) or (2) inadvertently counting individuals as multiple enrollees in multiple years
(ie, if an adolescent switched MarketScan-covered insurers). We analyzed data using SAS, version 9.4
(SAS Institute Inc). We report 95% CIs, which correspond to 2-sided tests of statistical significance at P < 
.05.
Results
Of the 1 224 520 new adolescent opioid recipients, 51.1% were female. The median age at first receipt was
17 years (interquartile range, 16-18 years). The median follow-up after first receipt was 625 days
(interquartile range, 255-1268 days).
During follow-up, adolescents filled 2 349 173 opioid prescriptions. Hydrocodone accounted for 61.6% of
opioids received (among 72.6% of recipients). Other common opioid products included oxycodone (21.9%
of recipients), codeine (18.8%), tramadol (7.3%), and propoxyphene (5.6%). Some adolescents received
multiple opioid drugs. Methadone (0.1% of prescriptions) was relatively uncommon.
Mental Health and Any Opioid Receipt
In comparisons of opioid recipients and matched nonrecipients, adolescents with most prior mental health
conditions and treatments were more likely than adolescents without such conditions or treatments to
receive any opioid (Table 1). Associations were generally weak in magnitude, with relative increases in the
odds of opioid receipt ranging from 13% for nonopioid SUDs (odds ratio [OR], 1.13; 95% CI, 1.10-1.16) to
69% for nonbenzodiazepine hypnotics (OR, 1.69; 95% CI, 1.58-1.81). Associations for suicide attempt or
other self-injury, schizophrenia spectrum disorders, OUD, and OUD medications were weaker and not
statistically significant. The Figure displays associations between prior mental health and receipt of any
opioid and LTOT.
Mental Health and LTOT
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Of the 1 000 453 opioid recipients (81.7%) with at least 6 months of follow-up, 51.1% were female, and the
median age was 17 years (interquartile range, 16-18 years). Among these adolescents, the estimated
cumulative incidence of LTOT after first opioid receipt was 1.1 (95% CI, 1.1-1.2) per 1000 recipients
within 1 year, 3.0 (95% CI, 2.8-3.1) per 1000 recipients within 3 years, 8.2 (95% CI, 7.8-8.6) per 1000
recipients within 6 years, and 16.1 (95% CI, 14.2-18.0) per 1000 recipients within 10 years. The prevalence
of mental health conditions and treatments in this sample is shown in eTable 3 in the Supplement.
All mental health conditions and treatments were associated with higher rates of transitioning from a first
opioid prescription to long-term therapy. Table 2 provides the estimated incidence of LTOT among those
with and without mental health conditions and treatments. Adjusted relative increases in the rate of LTOT
ranged from a factor of 1.73 for ADHD (hazard ratio [HR], 1.73; 95% CI, 1.54-1.95) to approximately
4-fold for benzodiazepines (HR, 3.88; 95% CI, 3.39-4.45) and nonopioid SUDs (HR, 4.02; 95% CI,
3.48-4.65) to 6-fold for nonbenzodiazepine hypnotics (HR, 6.15; 95% CI, 5.01-7.55) and to nearly 9-fold
for OUD (HR, 8.90; 95% CI, 5.85-13.54). In addition, relative to no condition, the number of condition
types was also associated with higher LTOT rates (1 condition: HR, 2.21; 95% CI, 2.01-2.43; 2 or more
conditions: HR, 4.01; 95% CI, 3.62-4.46).
Given the strong associations for OUD, we explored other mental health factors and opioid receipt among
those with preexisting OUD. These adolescents were more likely than adolescents without OUD to have
other mental health conditions and treatments (eTable 4 in the Supplement). For example, 76.1% of
adolescents with OUD had other SUDs, 61.0% had depressive disorders, and 52.6% had received an SSRI.
During follow-up, those with preexisting OUD received opioid drugs similar to those received by
adolescents without OUD, although the former were more likely to receive certain opioids (eg, oxycodone
and tramadol; eTable 5 in the Supplement). Of those with preexisting OUD, 15.5% filled a prescription for
OUD medication treatment during follow-up.
Sensitivity Analysis
Sensitivity analyses supported the overall LTOT conclusions (eTables 6 and 7 in the Supplement). First,
among the 229 913 opioid recipients (23.0%) with past 90-day painful condition diagnoses, the cumulative
incidence of LTOT was 6.6 (95% CI, 6.1-7.0) per 1000 within 3 years. Most mental health associations
persisted among these recipients. The HRs for LTOT ranged from 1.59 (ADHD medications 95% CI,
1.35-1.86) to 6.33 (nonbenzodiazepine hypnotics 95% CI, 4.84-8.26). Only the OUD medication
association was not statistically significant (HR, 2.23; 95% CI, 0.31-15.83).
Second, few tests of the proportional hazards assumption indicated changes in associations over time, and
none altered the overall interpretations. Associations were stronger earlier in follow-up for anxiety
disorders, benzodiazepines, sleep disorders, nonbenzodiazepine hypnotics, and, especially, OUD.
Extrapolating from the HR at the start of follow-up (13.93) and the interaction term, the OUD HR would
decrease to 5.25 by year 3.
Third and fourth, the results did not substantively differ for the stricter LTOT definition or past-year mental
health predictors, respectively. Fifth, associations were of comparable magnitudes for the 2010 index
cohort. As expected given the decreased statistical power, CIs were larger, although only the suicide
attempt or other self-injury, ADHD medication, and OUD medication associations were nonsignificant.
Discussion
In this nationwide study of commercially insured adolescents, LTOT was relatively uncommon. The
estimated incidence of LTOT receipt was 3.0 per 1000 adolescents within 3 years of filling an initial opioid
prescription. Although adolescents with a wide range of preexisting mental health conditions and
treatments were modestly more likely than adolescents without those conditions or treatments to receive an
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initial opioid, the former had substantially higher rates of subsequent transitioning to LTOT. Associations
were strongest for OUD, OUD medications, nonbenzodiazepine hypnotics, and other SUDs. The
associations were stronger sooner after first opioid receipt for OUD, as well as for anxiety and sleep
disorders and their treatments, suggesting that adolescents with these conditions and treatments were more
likely to quickly transition into LTOT.
These findings extend prior health care record studies of opioid receipt among young people. One smaller
study of adolescents and young adults with chronic pain found similar associations but lacked statistical
power to examine LTOT among those with SUDs.  Our prior study of MarketScan recipients across ages
included analyses of mental health and LTOT among adolescents and young adults but did not focus
primarily on adolescents.  The present results described among adolescents, in particular, nationwide
patterns of opioid initiation and LTOT across diverse preexisting mental health conditions and treatments.
Indeed, the magnitudes of those associations appeared equivalent or stronger than have been found for
older patients,  despite the relative rarity of LTOT among adolescents.
These results raise questions about how adolescents with mental health conditions—and OUD especially
—develop greater likelihoods of LTOT given no greater opioid effectiveness in these populations.
Adolescents with OUD appeared to differ primarily in the amount of opioids (ie, LTOT) rather than in
which opioid drugs they received. Hypotheses have been suggested at multiple levels of analysis.  For
example, researchers have proposed neurobiological vulnerabilities, including reward deficits.  At the
symptom level, chronic pain and mental health conditions are often comorbid, and mental health severity
may lead to intensification of pain.  Indeed, we found extensive mental health comorbidity among
adolescents with OUD. Moreover, decisions to write and to fill prescriptions likely result from complex
interactions among patients, guardians, and health care professionals. These decisions could reflect patient
distress and perceived need for care, stigma-related or other impediments to appropriate interventions, and
communication barriers among health care professionals.  Similarities between the present results
and findings for adults suggest commonalities in these processes across development.
Opioid prescription remains common overall,  and there is increasing recognition of overdose risk and
related health consequences.  Hospitalizations for self-inflicted opioid poisoning among adolescents have
increased,  and receipt of prescribed opioids among youths is associated with later misuse.  It is,
therefore, noteworthy that preexisting OUD and other SUDs, mood disorders, self-injurious behavior, and
multiple comorbid types of conditions were all substantially positively associated with receipt of LTOT in
the present analyses. There is a clear need for mental health assessment among adolescents being
considered for opioid therapy.  Such an assessment may help inform decision making regarding pain
treatment as well as illuminate the possible value of concomitant mental health interventions. In addition,
because of the associated overdose risk,  benzodiazepine-opioid combined therapy has been strongly
discouraged.  Associations found here between prior benzodiazepine receipt and opioid therapy highlight
the need to consider the potential risks of polypharmacy. We caution, however, that these data cannot
determine whether benzodiazepines and opioids were taken concurrently, whether they were prescribed by
the same health care professionals, or whether patient safeguards were put into place.
Limitations
Like other health care records research, this study was constrained by several limitations. First, MarketScan
data capture only conditions that were diagnosed and recorded in included claims, likely underestimating
the prevalence of SUDs and other mental health conditions.  Second, only claimed prescription fills are
recorded. Unfilled prescriptions and medications obtained via other means are not available.  For
example, although prior OUD diagnosis might indicate use of illicitly obtained opioids, it could also reflect
use of prescribed opioids not recorded in claims (eg, purchased out of pocket), which could help explain
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the association between OUD and LTOT.  Conversely, we could not confirm that adolescents consumed
the drugs obtained through their filled prescriptions. However, varying our predictor and outcome indices
produced converging results. Third, these data could not elucidate the severity of adolescents’ pain or
mental health conditions. Finally, this study was limited to commercially insured adolescents, although a
prior study found similar associations between mental health conditions and any opioid receipt among
adolescents enrolled in commercial insurance and Medicaid.
Conclusions
In this study of nationwide commercial health care claims, relatively few adolescents who received an
initial opioid subsequently transitioned to LTOT. Adolescents with preexisting mental health conditions and
treatments, however, were substantially more likely than adolescents without such conditions and
treatments to transition from opioid initiation to LTOT. Given the limited support for the efficacy of opioid
therapy for chronic pain among youths,  research is needed to understand potential adverse effects of LTOT
among adolescents as well as the role that preexisting mental health conditions may play in harmful
outcomes.
Notes
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eTable 1. International Classification of Diseases, Ninth Revision (ICD-9) Codes
eTable 2. Generic Drug Names
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eTable 4. Prior Mental Health Conditions and Treatments Among Adolescents With and Without
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Table 1.
Prior Mental Health Conditions and Treatments and Any Opioid Receipt
Prior Mental Health Factor No. (%) Odds Ratio (95% CI)
Nonrecipients (n = 489 704) Recipients (n = 489 704)
Anxiety
Anxiety disorder 20 649 (4.2) 26 005 (5.3) 1.28 (1.25-1.30)
Benzodiazepine 6880 (1.4) 11 079 (2.3) 1.63 (1.58-1.68)
Mood
Bipolar or other mood disorder 10 184 (2.1) 11 857 (2.4) 1.17 (1.14-1.20)
Depressive disorder 28 680 (5.9) 36 299 (7.4) 1.29 (1.27-1.31)
Suicide attempt or self-injury 1213 (0.2) 1263 (0.3) 1.04 (0.96-1.13)
Mood stabilizer 3336 (0.7) 4324 (0.9) 1.30 (1.24-1.36)
SNRI 1573 (0.3) 2453 (0.5) 1.56 (1.47-1.67)
SSRI 23 944 (4.9) 33 777 (6.9) 1.45 (1.42-1.47)
Neurodevelopment
ADHD 31 437 (6.4) 38 863 (7.9) 1.26 (1.24-1.28)
ADHD medication 34 213 (7.0) 44 929 (9.2) 1.35 (1.33-1.37)
Psychosis
Schizophrenia spectrum disorder 2259 (0.5) 2259 (0.5) 1.00 (0.94-1.06)
Antipsychotic 8663 (1.8) 10 196 (2.1) 1.18 (1.15-1.22)
Sleep
Sleep disorder 6444 (1.3) 8645 (1.8) 1.35 (1.31-1.39)
Nonbenzodiazepine hypnotic 1375 (0.3) 2318 (0.5) 1.69 (1.58-1.81)
Substance use
Nonopioid SUD 9037 (1.8) 10 189 (2.1) 1.13 (1.10-1.16)
OUD 612 (0.1) 564 (0.1) 0.92 (0.82-1.03)
OUD medication 206 (0.04) 203 (0.04) 0.99 (0.81-1.20)
Psychotherapy
For any diagnosis 40 820 (8.3) 55 390 (11.3) 1.41 (1.39-1.43)
Open in a separate window
Abbreviations: ADHD, attention-deficit/hyperactivity disorder; OUD, opioid use disorder; SNRI, serotonin-
norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; SUD, substance use disorder.
Randomly selected 40% of recipients matched 1:1 to nonrecipients on sex, months of enrollment, and age and year of
first enrollment.
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Figure.
Open in a separate window
Associations Between Prior Mental Health Conditions and Treatments and Subsequent Opioid Therapy
Any opioid receipt odds ratios are from conditional logistic regressions comparing opioid recipients (n = 489 704) with
nonrecipients matched 1:1 on sex, months of enrollment, and age and year of first enrollment. Long-term opioid therapy
hazard ratios are from Cox proportional hazards regressions analyzing the transition from first opioid receipt to long-term
opioid therapy, adjusting for sex and age and year of first opioid receipt (n = 1 000 453). Error bars indicate 95% CIs;
ADHD, attention-deficit/hyperactivity disorder; SNRI, serotonin-norepinephrine reuptake inhibitor; and SSRI, selective
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serotonin reuptake inhibitor.
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Table 2.
Prior Mental Health Conditions and Treatments and Long-term Opioid Therapy Among 1 
000 453 Adolescents
Prior Mental Health Factor Long-term Opioids per 1000 Recipients
Within 3 y
Hazard Ratio (95% CI)
No Predictor With Predictor Unadjusted Adjusted
Anxiety
Anxiety disorder 2.8 8.0 2.72 (2.42-3.06) 2.69 (2.39-3.03)
Benzodiazepine 2.8 12.2 4.07 (3.56-4.66) 3.88 (3.39-4.45)
Mood
Bipolar or other mood
disorder
2.8 10.1 3.33 (2.86-3.87) 3.28 (2.81-3.82)
Depressive disorder 2.6 9.0 3.15 (2.86-3.46) 3.01 (2.73-3.31)
Suicide attempt or self-injury 3.0 6.0 3.05 (1.73-5.38) 3.16 (1.79-5.58)
Mood stabilizer 2.9 10.3 3.12 (2.46-3.96) 3.01 (2.37-3.82)
SNRI 2.9 14.8 4.58 (3.59-5.85) 3.93 (3.08-5.02)
SSRI 2.6 9.1 3.11 (2.82-3.43) 2.95 (2.67-3.25)
Neurodevelopment
ADHD 2.9 4.5 1.64 (1.46-1.84) 1.73 (1.54-1.95)
ADHD medication 2.8 4.7 1.67 (1.50-1.85) 1.74 (1.56-1.94)
Psychosis
Schizophrenia spectrum
disorder
3.0 6.7 3.02 (2.11-4.32) 2.96 (2.07-4.24)
Antipsychotic 2.8 11.3 3.59 (3.08-4.18) 3.58 (3.08-4.17)
Sleep
Sleep disorder 2.9 10.8 3.58 (3.01-4.24) 3.53 (2.97-4.19)
Nonbenzodiazepine hypnotic 2.9 24.2 6.93 (5.65-8.50) 6.15 (5.01-7.55)
Substance use
Nonopioid SUD 2.8 12.7 4.33 (3.75-5.00) 4.02 (3.48-4.65)
OUD 3.0 27.5 9.74
(6.41-14.82)
8.90
(5.85-13.54)
OUD medication 3.0 22.4 9.83
(4.69-20.63)
8.50
(4.05-17.84)
Psychotherapy
Open in a separate window
Abbreviations: ADHD, attention-deficit/hyperactivity disorder; OUD, opioid use disorder; SNRI, serotonin-
norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; SUD, substance use disorder.
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Three-year cumulative incidence per 1000 opioid recipients.
Unadjusted Cox proportional hazards regression analysis.
Adjusted for sex, index age, and index year.
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